||EPS - Basic
||Market Cap (m)
|Health Care Equipment & Services
Real-Time news about 3D Diagnostic (London Stock Exchange): 0 recent articles
|multibagger: Thanks The graftman- different approaches to investing and each to his own. To me equity dilution is important, as I invest reasonable sums of money and hold 1-1.5% of a company. If they intend to issue shares, then it does not make sense for me to buy at a higher pre-placement price and then watch the price go down with the share dilution. Funding almost inevitably means that existing share holders get shafted.
My dentist friend called from Chicago and said that the service delivery environment is challenging and a number of high end practices are closing down due to the poor economic climate. She did not feel that the uptake of the product would be good for this reason at this time. Most patients have to pay for dental care and dentists are already cutting costs to retain patients - she does not think that she would invest in this equipment at this time.
I tried to buy 100k shares on Monday and had to keep reducing my online order to 10k before I got a quote...this put me off somewhat, as it appeared the liquidity is poor and it would take me ages and many trades to build a stake. I have not bothered since, but shall keep a watch on this and pick up when the risk-reward ratio is even better. Unfortunately, I do not think we have seen the bottom of the share price as yet.
All the very best to you and all who hold. Best wishes.|
|the avoint: 3D enters North American dental agreement
1 June 2011 | 11:22am
StockMarketWire.com - 3D Diagnostics Imaging has announced that its wholly owned subsidiary, CarieScan, has entered into an agreement with CoreStrength to manage its sales activity in both the U.S. and Canada (the "Agreement") for the CarieScan PRO (the easy to use hand held device for the early detection and monitoring of dental caries).
CarieScan will continue to work closely on a non-exclusive basis with Patterson Dental, its existing distribution partner in the U.S.
CoreStrength, which is well established in dental sales management, will provide CarieScan with access to a sales team of 22, substantially improving CarieScan's sales reach in those markets. Under the terms of the Agreement, CarieScan will contribute towards the costs of a jointly agreed marketing plan and towards certain costs incurred by CoreStrength in the delivery of its services.
The Agreement provides CarieScan with access to sales coverage for the whole of the North American territory on a predominantly commission only basis enabling the company to move forward on a significantly more cost effective manner.
As a consequence of entering into the Agreement and of moving away from directly employing sales support staff in the U.S. and Canada, the Directors believe that a significant proportion of the cost savings originally identified are now in place.
Commenting on the Agreement Graham Lay, 3D CEO, said: "I am delighted to be working with such a professional and experienced team and to achieve comprehensive coverage of the territory on such a cost effective basis."
At 11:22am: (LON:3DD) share price was +0.25p at 2.75p|
3D Diagnostic share price data is direct from the London Stock Exchange